Aro Biotherapeutics to Present Updates on ABX1100, a CD71 Centyrin – Gys1 siRNA Conjugate for the Treatment of Pompe Disease at the 20th Annual WORLD Symposium 2024 Meeting
Aro Biotherapeutics Announces Start of First in Human Study with ABX1100, a Novel First in Class Centyrin-siRNA Conjugate in Development for Pompe Disease